Overview of Dicycloverine

Here is a quick overview of dicycloverine (dicyclomine):

Property	Description
Active ingredient	Dicycloverine hydrochloride
Form	Oral tablet, capsule, or syrup
Pharmacological Class	Anticholinergic, Antispasmodic
Common use	Symptomatic relief of Irritable Bowel Syndrome (IBS)
Origin	Synthetic tertiary amine

Dicycloverine, also widely known by its generic name dicyclomine, is a prescription medication used primarily to relieve the painful symptoms associated with functional gastrointestinal disorders, most notably Irritable Bowel Syndrome (IBS).

This medication is classified as an anticholinergic and an antispasmodic agent. It is clinically recognized for its ability to reduce excessive motility and cramping within the gastrointestinal tract. Unlike simple pain relievers, dicycloverine specifically targets the smooth muscles of the stomach and intestines. This action is recognized for its effectiveness in patients experiencing functional bowel pain.

Dicycloverine hydrochloride is available as a generic drug in oral capsules, tablets, and a sweet, colorless liquid oral syrup—a form often favored for ease of administration. While the medication is an International Nonproprietary Name (INN), its formulation is commonly marketed under several brand names, such as Bentyl in the United States and Canada. The active ingredient, a synthetic tertiary amine, was first approved in the mid-20th century, establishing its long history and use in gastroenterology.

It is important to note that dicycloverine is a prescription-only (Rx) medication and is specifically contraindicated for infants younger than six months due to safety considerations related to its pharmacological class.

What side effects are possible with Dicycloverine?

Dicycloverine hydrochloride is an anticholinergic antispasmodic, and its safety profile is defined by effects across multiple physiological systems, as detailed in official regulatory sources. The most critical safety concerns are associated with specific patient populations and pre-existing conditions.

Officially Documented Adverse Reactions

The most frequently reported adverse reactions are classic anticholinergic effects, grouped by the FDA as Common (incidence greater than 5% of patients in clinical trials). European labeling often uses descriptive terms, such as Seldom Occur or On Rare Occasions.

System-Organ Class	Common Adverse Reactions
Gastrointestinal	Dry mouth, constipation, nausea, vomiting
Central Nervous System (CNS)	Dizziness, somnolence (drowsiness), asthenia (weakness), nervousness
Ophthalmologic	Blurred vision, increased ocular tension

Less frequent documented effects include headache, urinary retention, palpitations, rash, and psychological reactions such as mental confusion or excitement.

Serious Safety Considerations

Official regulatory documents specify several serious safety concerns and contraindications:

Infants lt 6 months of age: Dicycloverine is contraindicated due to the risk of serious respiratory complications, including apnea (cessation of breathing) and asphyxia.
Existing Conditions: The medication is contraindicated in patients with conditions such as glaucoma, obstructive uropathy, and obstructive disease of the gastrointestinal tract. Use with caution is necessary in patients with severe ulcerative colitis due to the potential risk of toxic megacolon.
CNS Effects: Severe reactions like psychosis and delirium have been reported, particularly in older adults, and these effects typically resolve within 12 to 24 hours after the drug is discontinued.
Heat Prostration: A risk of heat stroke can occur due to a documented reduction in sweating caused by the medication.

Overdose and Emergency Response

Suspected overdosage with dicycloverine requires immediate medical attention or contact with a Poison Control Center. The officially documented clinical manifestations are characteristic of excessive anticholinergic effects, affecting both the central and peripheral nervous systems.

Documented Overdose Presentation

Overdosage may present with nausea, vomiting, headache, dizziness, dryness of the mouth, difficulty in swallowing, and hot, dry skin. Ocular signs documented in regulatory sources include blurred vision and dilated pupils. CNS manifestations include excitement, confusion, disorientation, and hallucinations.

Severe Outcomes and Emergency Action

Severe outcomes documented in official labeling include curare-like action (neuromuscular blockade) potentially leading to paralysis, and episodes of psychosis in sensitive individuals. In the case of documented overdose symptoms, immediate medical care is required. Management procedures officially described include evacuation of stomach contents via gastric lavage or emetics, and the administration of activated charcoal. An appropriate parenteral cholinergic agent may be utilized as an antidote. The drug must be discontinued if signs of heat prostration occur. Infants under six months are a specific population where severe respiratory events, including apnea and death, have been reported following administration.

Therapeutic Uses of Dicycloverine

What Dicycloverine treats: main uses and benefits

Dicycloverine is used primarily to address symptoms associated with certain gastrointestinal conditions. It is indicated to help manage the muscle spasms of the stomach and intestines that can lead to discomfort. This medication may offer relief from acute occurrences of abdominal cramping, as well as the feelings of bloating and discomfort that often accompany these issues. The benefit for individuals is centered on promoting greater comfort within the digestive tract and assisting in the management of specific, uncomfortable symptoms.

Dicycloverine is utilized in clinical scenarios for the symptomatic management of functional bowel disorders and to address smooth muscle spasm in the gastrointestinal tract.

Quick Fact: Symptom Management
Dicycloverine may help to relieve cramping and manage the spasms associated with Irritable Bowel Syndrome (IBS) and other functional bowel issues.

Eligibility and Restrictions for Use

Who Can and Cannot Use Dicycloverine?

Official regulatory documents define strict criteria for dicycloverine eligibility, categorizing patient groups into those who must not use the medicine and those who require cautionary restrictions.

Absolute Contraindications

Dicycloverine is formally prohibited for several populations:

Age and Reproductive Status: Infants less than six months of age and nursing mothers.
Comorbidities: Patients with glaucoma, myasthenia gravis, obstructive uropathy, obstructive disease of the gastrointestinal tract, severe ulcerative colitis, reflux esophagitis, or unstable cardiovascular status in acute hemorrhage.

Eligibility by Age and Cautionary Use

Population Group	Regulatory Status	Restriction Context
Adults	Eligible	Permitted for the approved indication, barring contraindications.
Pediatric (6+ months)	Use Not Established	Safety and effectiveness have not been established in children older than six months.
Older Adults	Use with Caution	Increased susceptibility to adverse effects is noted.
Renal/Hepatic Impairment	Use with Caution	Required due to the drug's excretion pathway and risk of systemic exposure.

Caution is also mandated for patients with prostatic hypertrophy, autonomic neuropathy, and certain cardiac conditions, including hypertension and congestive heart failure.

What should I know about interactions with other medicines?

Dicycloverine's interaction profile is defined by its anticholinergic properties and its effect on gastrointestinal motility, which can lead to additive effects or altered drug absorption. The official regulatory documents cite several pharmacodynamic and pharmacokinetic interaction patterns.

Co-administration with other anticholinergic agents or Opioid Analgesics carries a documented risk of additive effects, such as increased urinary retention and severe constipation. Due to its action on gastrointestinal smooth muscle, dicyclomine can antagonize the effects of prokinetic agents like Metoclopramide. Furthermore, dicycloverine may decrease the absorption of sublingual Nitroglycerin.

Regarding absorption, the co-administration of Antacids should be avoided as they interfere with dicycloverine's absorption, necessitating time separation. Conversely, dicycloverine may slow gastrointestinal transit, potentially resulting in increased serum concentrations of other drugs, notably slowly dissolving dosage forms of Digoxin.

Interaction Type	Interacting Substance	Official Outcome
Additive Effect	Other Anticholinergic Agents	Increased specific anticholinergic actions
Absorption Interference	Antacids	Reduced dicycloverine exposure (requires separation)
CNS Depression	Ethanol (Alcohol)	Increased documented drowsiness and dizziness

Special caution is noted in regulatory documents for Geriatric Patients, who may be more susceptible to adverse events when combining dicycloverine with other agents. Caution is also advised in patients with hepatic or renal impairment due to the risk of drug build-up, which can heighten the severity of co-administered drug effects.

Mechanism of Action

The action of Dicycloverine involves a dual pharmacological mechanism influencing the smooth muscle tone of the gastrointestinal (GI) tract, targeting the signals responsible for heightened smooth muscle contraction and hypermotility.

Blocking the "Contract" Signal (Muscarinic Antagonism)

Dicycloverine acts as a non-selective antagonist at muscarinic acetylcholine receptors (M1, M2, M3) found on intestinal smooth muscle cells. This action interrupts the signal from the parasympathetic nervous system, specifically preventing the neurotransmitter Acetylcholine ( ACh) from binding to the receptors. This suppression of the primary excitatory signal leads directly to a reduction in muscle tone and contraction frequency.

Direct Muscle Relaxation (Musculotropic Effect)

The second mechanistic domain involves a direct musculotropic effect, which is independent of the cholinergic receptors. Dicycloverine exerts a non-competitive inhibitory action directly on the smooth muscle fiber itself. This mechanism acts in conjunction with the primary anticholinergic effect, influencing the smooth muscle's inherent excitability.

Systemic Effects of Non-Selective Receptor Binding

Since Dicycloverine is a non-selective muscarinic antagonist and can cross the blood-brain barrier, its mechanism extends beyond the gut. It also blocks receptors in other systems, leading to secondary physiological consequences such as reduced glandular secretions (e.g., salivation) and, at high levels, the potential for central anticholinergic activity.

Dosage and Administration Information

Administration Routes and Methods

Dicycloverine is administered through two approved routes: oral (using tablets, capsules, or syrup) and intramuscular (IM) injection. The standard adult oral regimen typically begins with 20 mg four times a day. If necessary, the dose may be increased to a maximum of 40 mg four times a day, resulting in a maximum daily dose of 160 mg. Alternatively, some regimens outline a dose range of 10 mg to 20 mg three times daily. The oral syrup can be administered directly or diluted with water or syrup immediately prior to use.

Intramuscular Injection Requirements

The injectable formulation is strictly restricted to the intramuscular route; administration via the intravenous (IV) route is forbidden. When administering the IM injection, the syringe must be aspirated prior to injection to avoid accidental intravascular entry. IM administration is intended for short-term use only, typically lasting one or two days, before transitioning the patient to the oral form.

Usage Constraints and Duration

Treatment should be discontinued if the necessary therapeutic effect is not achieved within a two-week period. Use is also subject to age-specific constraints, as the medication is contraindicated for infants younger than six months of age.

Recent Clinical Evidence

Recent Clinical Evidence Overview

Dicycloverine, also known as dicyclomine, is classified as an antispasmodic agent used primarily to manage the symptoms of functional bowel/irritable bowel syndrome (IBS). The majority of clinical support for this agent is rooted in earlier randomized, placebo-controlled trials, although it is still included in clinical guidelines as a pharmacological option for IBS.

Efficacy and Study Outcomes

IBS Symptom Relief: A key trial from the early 1980s, which remains foundational for the drug’s evidence, compared dicycloverine to placebo in adult patients with IBS. In this study, a favorable clinical response was observed in a significantly higher percentage of participants receiving dicycloverine than those on placebo. Outcomes assessed included overall condition, abdominal pain, and bowel habits.
Antispasmodic Class Review: Systematic reviews and meta-analyses examining antispasmodic agents as a class (which includes dicycloverine) have generally indicated an improvement in abdominal pain and overall global assessment scores compared to placebo in patients with IBS. However, the quality of evidence supporting the use of dicycloverine specifically is often described as limited in these reviews.

Safety and Tolerability

Clinical data consistently show that the most common adverse events reported are related to the drug’s anticholinergic mechanism of action.

Common Observed Effects
Dry mouth, blurred vision, dizziness
Constipation, nausea, drowsiness

These events are typically dose-related. Experts recommend individualizing treatment and dose titration to manage the potential occurrence of side effects, particularly in older adult patients who may be more susceptible to anticholinergic effects.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Dicycloverine (FAQ)

Q: Is Dicycloverine a strong painkiller?

A: Dicycloverine is officially classified as an antispasmodic agent. It works by relaxing the smooth muscles in the gut to provide symptomatic relief from pain caused by intestinal spasms, such as those associated with Irritable Bowel Syndrome (IBS). It is not typically classified as a general analgesic (painkiller) drug.

Q: Can Dicycloverine affect driving ability?

A: Official product information warns that Dicycloverine can cause side effects like dizziness, drowsiness (somnolence), and blurred vision. Individuals who experience these effects are often cautioned against activities that require alertness, such as driving or operating machinery.

Q: Does Dicycloverine interact with anxiety or depression medicines?

A: Regulatory documents indicate a potential risk of additive effects when Dicycloverine is taken with other medicines that also have anticholinergic activity. This can include certain medications used for anxiety or depression. The combination carries a potential for increased anticholinergic effects like drowsiness and dry mouth.

Q: What is Dicycloverine chemically similar to?

A: Dicycloverine hydrochloride is chemically classified as a synthetic tertiary amine. It belongs to the class of anticholinergic agents and is structurally similar to other compounds used for muscle relaxation in the gut.

Q: Is Dicycloverine the same kind of medicine as Hyoscyamine?

A: Dicycloverine and Hyoscyamine are both distinct chemical medicines that belong to the same broad pharmacological class: anticholinergic antispasmodic agents. They are both used to treat functional gastrointestinal disorders like IBS, but they are not the same exact drug.

Q: Can you take Dicycloverine if you are pregnant?

A: Regulatory documents advise that the drug should only be used during pregnancy if the potential benefit justifies the potential risk to the developing fetus. Official guidance suggests consulting a healthcare professional if pregnant or planning to become pregnant.

Q: Can Dicycloverine be used with acid reflux medications?

A: Dicycloverine is officially contraindicated (prohibited) for patients diagnosed with reflux esophagitis (inflammation of the esophagus due to reflux). Additionally, regulatory instructions advise avoiding the co-administration of Antacids because they can interfere with the proper absorption of Dicycloverine.

Q: Is Dicycloverine a medication that people take long-term?

A: The regulatory label sets time limits for oral therapy. If a satisfactory therapeutic effect is not achieved within a two-week period, treatment should be officially discontinued. Safety data for chronic use, particularly beyond the specified two-week window for oral therapy, may be limited in official labeling.

Q: Is it possible to have an allergic reaction to Dicycloverine?

A: Yes, official regulatory information indicates that Dicycloverine is contraindicated in patients with a known hypersensitivity or allergy to dicycloverine hydrochloride or any of its inactive ingredients. Allergic reactions, while not common, are a documented possibility.

Q: Are there different strengths of Dicycloverine available?

A: Yes, Dicycloverine is available in various dosage forms and strengths, as described in official labeling. These generally include oral options such as 10 mg capsules, 20 mg tablets, and an oral syrup.

Q: Is Dicycloverine used to treat nausea?

A: Nausea is listed in regulatory documents as a potential side effect of the medication. The drug’s primary regulatory indication is the symptomatic relief of Irritable Bowel Syndrome (IBS) and associated gastrointestinal spasms, not the treatment of nausea itself.

Q: What is the difference between Dicycloverine and peppermint oil?

A: Dicycloverine is a prescription-only synthetic drug regulated as an anticholinergic agent. Peppermint oil, while sometimes used for similar gastrointestinal symptoms, is typically used as a botanical or dietary supplement and is not regulated as a prescription drug.

Q: Can Dicycloverine cause headaches?

A: Yes, official documentation on adverse events lists headache as a documented reaction associated with the use of Dicycloverine. While not one of the most common side effects, it is a possibility noted in the data.

Q: Does Dicycloverine interact with over-the-counter pain relievers?

A: Regulatory documents primarily caution against the co-administration of Dicycloverine with other anticholinergic agents and opioid pain relievers due to the risk of additive effects like constipation. Interactions with other common over-the-counter pain relievers are not specifically detailed in the official safety information.

Q: Can Dicycloverine be taken on an empty stomach?

A: Some official dosing instructions recommend that Dicycloverine be taken before or after meals for proper use. Certain patient guidance suggests taking it 30 to 60 minutes before a meal.

Q: What happens if I stop taking Dicycloverine suddenly?

A: Official patient information cautions that stopping the medication abruptly may result in the return of symptoms that the medication was intended to manage, such as spasms or pain. Patients are cautioned against discontinuing the medication without consulting a healthcare professional.

Q: What is the drug-drug interaction category for Dicycloverine?

A: Within the official Anatomical Therapeutic Chemical (ATC) classification system, Dicycloverine belongs to the group of Synthetic anticholinergics used for Functional Gastrointestinal Disorders (category A03AA07).

Q: Does Dicycloverine work the same way for everyone?

A: No. Official regulatory documents indicate that treatment should be individualized based on how each patient responds to the drug and their tolerance for potential adverse effects. This highlights that the effects and tolerability can vary from person to person.

Q: Can Dicycloverine be used for general stomach cramping?

A: Dicycloverine is formally indicated for the symptomatic treatment of spasms associated with Irritable Bowel Syndrome (IBS). While its mechanism works on smooth muscle throughout the gut to relieve cramping, its approved use is tied to functional gastrointestinal disorders.

Q: Does Dicycloverine affect the brain directly?

A: Yes. Official documents detail effects on the Central Nervous System (CNS), including side effects like dizziness, somnolence, and nervousness. Severe reactions like confusion and delirium have also been reported, indicating activity extending beyond the digestive tract.

Q: Is it normal to feel a bit flushed after taking Dicycloverine?

A: Flushed skin is a documented possible adverse effect of Dicycloverine in patient information. Additionally, the drug's action can reduce sweating, which is officially linked to a risk of heat prostration (heat stroke), a related autonomic effect.

Q: Are there long-term safety studies on Dicycloverine?

A: The official label sets a maximum treatment window of two weeks for oral therapy, and safety data for chronic use at certain doses are often limited. Efficacy support primarily comes from earlier, foundational trials and systematic reviews of the antispasmodic class.

How should Dicycloverine be stored and disposed of?

How to Store and Dispose of Dicycloverine?

Regulatory agencies define specific conditions for storing and disposing of dicycloverine to ensure its stability and safety. The medication must be kept at Controlled Room Temperature, defined as 20^circ to 25 C (68^circ to 77 F), and must be protected from both freezing and excessive heat.

Storage Requirement	Rule
Temperature & Light	Store at CRT; protect from excessive heat, freezing, and direct sunlight.
Packaging	Keep in the original container, tightly closed; the oral solution requires a child-resistant closure.
Stability	The oral solution has a 6-month shelf life after the container is first opened.

It is mandatory to keep dicycloverine out of the sight and reach of children.

For disposal, unused or expired medication must be managed according to local requirements. Official instructions advise against throwing it in the household trash or flushing it into wastewater; instead, utilize a drug take-back program.

Dicycloverine